Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma

被引:86
作者
Geisler, JP [1 ]
Goodheart, MJ [1 ]
Sood, AK [1 ]
Holmes, RJ [1 ]
Hatterman-Zogg, MA [1 ]
Buller, RE [1 ]
机构
[1] Univ Iowa Hosp & Clin, Holden Comprehens Canc Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Iowa City, IA USA
关键词
mismatch repair; mRNA; CpG island methylation; microsatellite instability; ovarian carcinoma;
D O I
10.1002/cncr.11770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. hMLH1, the human MutL homologue, has been linked to microsatellite instability (MSI) in gastrointestinal tumors. However, to the authors' knowledge, the role of hMLH1, the other mismatch repair genes (MMR), and MSI in ovarian carcinoma has not been well defined. The purpose of the Current study was to determine the relation between NISI of ovarian carcinoma and MMR gene expression, hMLH1 and hMSH2 hypermethylation, and hMLH1 and hMSH2 null Mutations. METHODS. hMLH1 mRNA was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and amplification of cDNA using a housekeeping gene (glycerol 3-phosphate dehydrogenase) as a control for mRNA quality and quantity. Methylation-specific PCR (MS-PCR) was used to correlate methylation of the hMLH1 and hMSH2 CpG islands with mRNA expression status. Similar techniques were used to evaluate the concomitant expression of five other MMR: hMSH2, hMSH3, hMSH6, PMS1, and PMS2. Microsatellite instability was studied using the National Cancer Institute consensus markers (D2S123, D5S346, D17S250, BAT25, and BAT26) and NM23 as described previously. RESULTS. One hundred twenty-five primary tumors were analyzed. High-frequency MSI (NISI-H) was found in 21 tumors (16.8%). hMLH1 mRNA was absent in 10 of these 21 tumors (47.6%). In each case, coordinated hypermethylation of both regions A and C of the promoter was identified. Microsatellite stable and low-frequency MSI tumors all were found to express not only hMLH1 but the other MMR genes as well (P < 0.001). Absence of expression of hMSH2 and the four other MMRs occurred in tumors with absent hMLH1 mRNA expression because of CpG island hypermethylation. No absence of expression of hMSH2, hMSH3, hMSH6, PMS1, or PMS2 was found to occur in tumors expressing hMLH1. None of the 11 MSI-H tumors without promoter hypermethylation demonstrated a null mutation in hMLH1 or hMSH2. CONCLUSIONS. A molecular mechanism to explain > 50% of the NISI-H phenotype in ovarian carcinoma cases was demonstrated. MSI-H may occur because of MMR defects, especially hMLH1 promoter hypermethylation. Additional mechanisms are required to explain the balance between the cases of MSI-H as well as the phenomenon of MSI-L tumors. 2003 American Cancer Society.
引用
收藏
页码:2199 / 2206
页数:8
相关论文
共 48 条
[1]   Microsatellite instability in ovarian and other pelvic carcinomas [J].
Allen, HJ ;
DiCioccio, RA ;
Hohmann, P ;
Piver, MS ;
Tworek, H .
CANCER GENETICS AND CYTOGENETICS, 2000, 117 (02) :163-166
[2]   Microsatellite instability differences between familial and sporadic ovarian cancers [J].
Arzimanoglou, II ;
Lallas, T ;
Osborne, M ;
Barber, H ;
Gilbert, F .
CARCINOGENESIS, 1996, 17 (09) :1799-1804
[3]  
Boland CR, 1998, CANCER RES, V58, P5248
[4]   Field cancerization: Why late "recurrent" ovarian cancer is not recurrent [J].
Buller, RE ;
Skilling, JS ;
Sood, AK ;
Plaxe, S ;
Baergen, RN ;
Lager, DJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 178 (04) :641-649
[5]   p53 mutations and microsatellite instability in ovarian cancer: Yin and Yang [J].
Buller, RE ;
Shahin, MS ;
Holmes, RW ;
Hatterman, M ;
Kirby, PA ;
Sood, AK .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (05) :891-902
[6]   Steady-state regulation of the human DNA mismatch repair system [J].
Chang, DK ;
Ricciardiello, L ;
Goel, A ;
Chang, CL ;
Boland, CR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (24) :18424-18431
[7]  
CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
[8]  
Codegoni AM, 1999, ONCOL RES, V11, P297
[9]   hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors [J].
Colella, G ;
Vikhanskaya, F ;
Codegoni, AM ;
Bonazzi, C ;
D'Incalci, M ;
Broggini, M .
CARCINOGENESIS, 1998, 19 (04) :691-694
[10]  
Deng GR, 1999, CANCER RES, V59, P2029